A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors
Latest Information Update: 25 Jul 2025
At a glance
- Drugs Enol oxaloacetate (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
Most Recent Events
- 15 Jul 2025 Planned End Date changed from 1 Nov 2026 to 12 Nov 2024.
- 15 Jul 2025 Planned primary completion date changed from 1 Nov 2025 to 12 Nov 2024.
- 15 Jul 2025 Status changed from recruiting to completed.